Zobrazeno 1 - 8
of 8
pro vyhledávání: '"S. M. Hulting"'
Publikováno v:
Journal of Clinical Oncology. 23:8095-8095
8095 Background: The relationship between quality of life (QoL) and morbidity and mortality in metastatic hormone-refractory prostate cancer (M+HRPC) remains unclear. The role of QoL as a predictor...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::88235776725ee95611ed0ce327f18cbe
https://doi.org/10.1200/jco.2005.23.16_suppl.8095
https://doi.org/10.1200/jco.2005.23.16_suppl.8095
Publikováno v:
Journal of Clinical Oncology. 22:4554-4554
4554 Background: Prostate-specific antigen doubling time (PSADT) has been identified as a predictor of outcome in prostate cancer. Atrasentan, a potent, selective, oral endothelin A receptor antago...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::95328623933ca2ee87ad1c72eb0d06a2
https://doi.org/10.1200/jco.2004.22.90140.4554
https://doi.org/10.1200/jco.2004.22.90140.4554
Publikováno v:
Journal of Clinical Oncology. 22:4655-4655
4655 Background: Bone alkaline phosphatase (BAP) has been validated as a potential predictor of survival in hormone-refractory prostate cancer (HRPC) patients. Phase 2 results show that atrasentan,...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e8d5c0379ce2b2e530986560d1e32aaf
https://doi.org/10.1200/jco.2004.22.90140.4655
https://doi.org/10.1200/jco.2004.22.90140.4655
Publikováno v:
Journal of Clinical Oncology. 22:4688-4688
4688 Background: Markers of osteoblastic activity, in particular bone alkaline phosphatase (BAP), increase in hormone refractory prostate cancer (HRPC) patients. BAP has been shown to be as valuabl...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::be3129c74b8e3f10f0a4e1dfdd2325a9
https://doi.org/10.1200/jco.2004.22.90140.4688
https://doi.org/10.1200/jco.2004.22.90140.4688
Autor:
David P. Dearnaley, Claude Schulman, Jeffrey D. Isaacson, D. J. Sleep, Fred Saad, S. M. Hulting, Joel B. Nelson, P. Nisen, Michael A. Carducci, A. R. Allen
Publikováno v:
Journal of Clinical Oncology. 22:4508-4508
4508 Background: In earlier trials, atrasentan, a potent, selective, oral endothelin A receptor antagonist, significantly delays time to disease progression (TTP) in a per-protocol group of hormone...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ed32356fe5d2c1a41bd102f0fd91eab8
https://doi.org/10.1200/jco.2004.22.90140.4508
https://doi.org/10.1200/jco.2004.22.90140.4508
Autor:
S. Yount, D. J. Sleep, Jeffrey D. Isaacson, A. R. Allen, S. M. Hulting, P. Mulani, T. Ashsraf, David Cella
Publikováno v:
Journal of Clinical Oncology. 22:4582-4582
4582 Background: For men with advanced cancer facing reduced life expectancy and no possibility of cure, symptom relief and maintenance of function are primary objectives of treatment. The Function...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::de8aaecbef2cbc85579df37d19ed3396
https://doi.org/10.1200/jco.2004.22.90140.4582
https://doi.org/10.1200/jco.2004.22.90140.4582
Publikováno v:
Journal of Clinical Oncology. 22:4687-4687
4687 Background: Bone alkaline phosphatase (BAP) predicts time to progression (TTP) and survival in patients with hormone refractory prostate cancer (HRPC). We tested 2 hypotheses: a) BAP at baseli...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f0b6c63b6ac8272fb5d788a84f97a48c
https://doi.org/10.1200/jco.2004.22.90140.4687
https://doi.org/10.1200/jco.2004.22.90140.4687
Autor:
David P. Dearnaley, L. Coetzee, A. R. Allen, Bernard A. Zonnenberg, S. M. Hulting, D. J. Sleep, Claude Schulman, J. Isaacson
Publikováno v:
European Urology Supplements. 3:157
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d78ef051c98f448e9445787ad5ed69e9
https://doi.org/10.1016/s1569-9056(04)90611-2
https://doi.org/10.1016/s1569-9056(04)90611-2